ijms-logo

Journal Browser

Journal Browser

Inflammatory Signaling Pathways Involved in Gastrointestinal Diseases: Second Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 20 July 2025 | Viewed by 4628

Special Issue Editors


E-Mail Website
Guest Editor
Section of Biochemistry, Department of Biomedicine, Neurosciences and Advanced Diagnostics (BIND), University of Palermo, 90127 Palermo, Italy
Interests: inflammatory diseases; cancer; oxidative stress; biochemical mechanisms of cell death and survival (apoptosis, necrosis, autophagy); nutraceuticals; food intolerance
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor

Special Issue Information

Dear Colleagues,

Inflammation is a defensive response of the innate and adaptive immune systems against injury and/or harmful microorganisms that restores homeostasis. The importance of inflammatory signaling pathways in diseases has been recognized, and the signaling molecules implicated in these pathways are thought to be promising targets for the development of new therapeutic strategies. Many studies have demonstrated that inflammation-related signaling pathways influence the homeostasis and health of the human gastrointestinal system.

The main goal of this Special Issue is to shed light, through both original research and review articles, on the role of immune inflammatory signaling pathways in gastrointestinal inflammation and tumors, and on the latest progress in understanding the corresponding regulatory mechanisms. We also welcome research papers evaluating strategies to reduce inflammation in inflammatory gastrointestinal diseases. Moreover, this Special Issue explores the effects and mechanisms of different signaling pathways in tumors such as gastric cancer and colorectal cancer, as well as inflammatory diseases such as inflammatory bowel disease (IBD), intestinal-related sepsis, colonitis and celiac disease. Complete knowledge of the inflammatory signaling pathways could be helpful not only for the prevention but also for the novel treatment of these diseases.

Generally, pure clinical research or model studies, survey studies and correlation research are outside of the scope of IJMS. However, clinical or model studies that involve biomolecular experiments are welcomed.

This Special Issue is supervised by Dr. Diana Di Liberto and Prof. Dr. Marianna Lauricella, who are assisted by our Topical Advisory Panel Member Dr. Giovanni Pratelli (University of Palermo).

Dr. Diana Di Liberto
Prof. Dr. Marianna Lauricella
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory signaling pathways
  • gastrointestinal diseases
  • gastrointestinal cancer
  • inflammatory bowel disease
  • colonitis
  • colorectal cancer
  • cytokine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 3029 KiB  
Article
Glyburide Suppresses Inflammation-Related Colorectal Tumorigenesis Through Inhibition of NLRP3 Inflammasome
by Toshihide Maeda, Yohei Shirakami, Daisuke Taguchi, Takao Miwa, Masaya Kubota, Hiroyasu Sakai, Takashi Ibuka, Kosuke Mori, Hiroyuki Tomita and Masahito Shimizu
Int. J. Mol. Sci. 2024, 25(21), 11640; https://doi.org/10.3390/ijms252111640 - 30 Oct 2024
Cited by 2 | Viewed by 1252
Abstract
Colorectal cancer represents one of the most serious complications of inflammatory bowel disease. The NLRP3 inflammasome plays a pivotal role in the onset and progression of inflammatory bowel disease and is also implicated in colorectal cancer. This study aimed to investigate whether NLRP3 [...] Read more.
Colorectal cancer represents one of the most serious complications of inflammatory bowel disease. The NLRP3 inflammasome plays a pivotal role in the onset and progression of inflammatory bowel disease and is also implicated in colorectal cancer. This study aimed to investigate whether NLRP3 deficiency or glyburide, a sulfonylurea used for diabetes management and known as an NLRP3 inhibitor, could suppress colitis and its related colorectal tumorigenesis. Mice were divided into three groups: a control group, a glyburide group, and an NLRP3-deficient group. We investigated acute colitis and inflammation-related tumor models using azoxymethane and dextran sodium sulfate. In the colitis model, the colonic inflammation grade was significantly increased in NLRP3-deficient mice but not in mice administered glyburide. In the colorectal carcinogenesis model, fewer colorectal tumors were observed in both NLRP3-deficient and glyburide-treated groups. Additionally, a reduction in the expression levels of inflammatory cytokine genes was detected in the colonic mucosa of the mice of these groups. These findings suggest that NLRP3 deficiency may exacerbate acute colitis, while pharmacological inhibition, as well as deficiency of NLRP3, suppresses colitis-related tumorigenesis, presumably due to the attenuation of chronic inflammation in the colorectum. Glyburide holds promise as a potential chemopreventive agent for colitis-related colorectal cancer. Full article
Show Figures

Figure 1

Review

Jump to: Research

15 pages, 3475 KiB  
Review
Eosinophils in Colorectal Cancer: Emerging Insights into Anti-Tumoral Mechanisms and Clinical Implications
by David Lopez-Perez, Belen Prados-Lopez, Julio Galvez, Josefa Leon and Angel Carazo
Int. J. Mol. Sci. 2024, 25(11), 6098; https://doi.org/10.3390/ijms25116098 - 1 Jun 2024
Cited by 4 | Viewed by 2594
Abstract
Eosinophils are myeloid effector cells whose main homing is the gastrointestinal tract. There, they take part in type I and type II immune responses. They also contribute to other non-immunological homeostatic functions like mucus production, tissue regeneration, and angiogenesis. In colorectal cancer (CRC), [...] Read more.
Eosinophils are myeloid effector cells whose main homing is the gastrointestinal tract. There, they take part in type I and type II immune responses. They also contribute to other non-immunological homeostatic functions like mucus production, tissue regeneration, and angiogenesis. In colorectal cancer (CRC), eosinophils locate in the center of the tumor and in the front of invasion and play an anti-tumoral role. They directly kill tumor cells by releasing cytotoxic compounds and eosinophil extracellular traps or indirectly by activating other immune cells via cytokines. As CRC progresses, the number of infiltrating eosinophils decreases. Although this phenomenon is not fully understood, it is known that some changes in the microenvironmental milieu and microbiome can affect eosinophil infiltration. Importantly, a high number of intratumoral eosinophils is a favorable prognostic factor independent from the tumor stage. Moreover, after immunotherapy, responding patients usually display eosinophilia, so eosinophils could be a good biomarker candidate to monitor treatment outcomes. Finally, even though eosinophils seem to play an interesting anti-tumoral role in CRC, much more research is needed to fully understand their interactions in the CRC microenvironment. This review explores the multifaceted roles of eosinophils in colorectal cancer, highlighting their anti-tumoral effects, prognostic significance, and potential as a biomarker for treatment outcomes. Full article
Show Figures

Figure 1

Back to TopTop